Clinical features of patients
Patients . | Date of HIV diagnosis . | CDC stage . | ARV treatment . | CD4 count, cells/mm3 . | HIV-RNA log, copies/mL . | Previous MCD treatment . | Associated treatment . | Associated pathology . | Clinical outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1997 | A2 | d4T/ddl/EFV | 635 | < 2.3 | Vinblastine (2 y) | None | None | CR |
| 2 | 1989 | C3 | EFV/APV/LPV | 669 | < 2.3 | Vinblastine (6 y) | IVIG | KS, MAS, neutropenia | Death |
| 3 | 2000 | C3 | d4T/3TC/NVP | 170 | < 2.3 | None | IVIG, vinblastine, corticoids | KS, hemolytic anemia | Death |
| 4 | 1998 | C3 | ZDV/3TC/ABC | 76 | 3.9 | Vinblastine (2 inf) | None | KS | CR |
| 5 | 1997 | C3 | ddl/3TC/TDF/EFV/LPV | 192 | < 2.3 | None | None | KS | CR |
Patients . | Date of HIV diagnosis . | CDC stage . | ARV treatment . | CD4 count, cells/mm3 . | HIV-RNA log, copies/mL . | Previous MCD treatment . | Associated treatment . | Associated pathology . | Clinical outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1997 | A2 | d4T/ddl/EFV | 635 | < 2.3 | Vinblastine (2 y) | None | None | CR |
| 2 | 1989 | C3 | EFV/APV/LPV | 669 | < 2.3 | Vinblastine (6 y) | IVIG | KS, MAS, neutropenia | Death |
| 3 | 2000 | C3 | d4T/3TC/NVP | 170 | < 2.3 | None | IVIG, vinblastine, corticoids | KS, hemolytic anemia | Death |
| 4 | 1998 | C3 | ZDV/3TC/ABC | 76 | 3.9 | Vinblastine (2 inf) | None | KS | CR |
| 5 | 1997 | C3 | ddl/3TC/TDF/EFV/LPV | 192 | < 2.3 | None | None | KS | CR |
CDC indicates Centers for Disease Control and Prevention Disease Status; ARV, antiretroviral; d4T, stavudine; 3TC, lamivudine; ZDV, zidovudine; ddl, didanosine; ABC, abacavir; TDF, tenofovir; APV, amprenavir; LPV, lopinavir; EFV, efavirenz; NVP, nevirapine; MCD, multicentric Castleman disease; IVIG, intravenous immunoglobulin; inf, infusions; KS, Kaposi sarcoma; MAS, macrophagic-activating syndrome; and CR, complete remission.